Detalles de la búsqueda
1.
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Circulation
; 2024 Apr 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38583093
2.
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
J Am Soc Nephrol
; 34(12): 1965-1975, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37876229
3.
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Diabetes Obes Metab
; 25(8): 2151-2162, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37161691
4.
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Circulation
; 143(18): 1735-1749, 2021 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33554616
5.
GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.
Kidney Int
; 101(2): 360-368, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34826514
6.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
N Engl J Med
; 380(24): 2295-2306, 2019 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30990260
7.
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Am J Kidney Dis
; 79(2): 244-256.e1, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34029680
8.
Antiplatelet agents for chronic kidney disease.
Cochrane Database Syst Rev
; 2: CD008834, 2022 02 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35224730
9.
Risk factors for incident kidney disease in older adults: an Australian prospective population-based study.
Intern Med J
; 52(5): 808-817, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33012112
10.
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Eur Heart J
; 42(48): 4891-4901, 2021 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34423370
11.
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
JAMA
; 327(19): 1888-1898, 2022 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35579642
12.
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Stroke
; 52(5): 1545-1556, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33874750
13.
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
Kidney Int
; 99(4): 999-1009, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33316282
14.
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Am J Kidney Dis
; 77(1): 23-34.e1, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32971190
15.
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.
Am J Nephrol
; 52(10-11): 827-836, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34731857
16.
The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
Diabetes Obes Metab
; 23(3): 763-773, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33269512
17.
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis.
Diabetes Obes Metab
; 23(12): 2707-2715, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34402161
18.
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
Diabetes Obes Metab
; 23(2): 382-390, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33043620
19.
Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial.
Diabetes Obes Metab
; 23(6): 1420-1425, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33606920
20.
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
Diabetes Obes Metab
; 23(7): 1652-1659, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33769679